Racura Oncology Ltd · ASX:RAC
Racura Oncology — Shareholder Meeting (November 2021)
30 slides from Racura Oncology's shareholder meeting presentation, Nov 23, 2021
Slide 1: Race 2021 AGM Presentation (ASX Announcement)
ASX Announcement Race 2021 AGM Presentation Race provides a strategic update to its “Three Pillar” strategy, including extending Zantrene’s use to the new area of cardio-protection; enhancing Zantrene’s utility for solid tumours through new formulations, and commencing a program to develop new RNA
Slide 2: Chairman's address, 2021 AGM
Chairman’s address, 2021 AGM Fellow shareholders, I’m pleased to welcome you to Race’s 2021 Annual General Meeting. This AGM is being conducted in a fully virtual environment to enable participation of all those around the world affected by the ongoing pandemic. Wherever you’re joining us from today
Slide 3: Chairman's address (continued)
Today’s AGM sees us supported by a stronger Board and Management team, and I’d like to acknowledge Mary Harney who joined us this year in a non-executive capacity, bringing significant life science, academic and governance skills to the Board. The Executive team is far stronger today with the additi
Slide 4: About Race Oncology
About Race Oncology (ASX: RAC) Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®. Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a divers
Slide 5: Novel RNA-Directed Therapeutics to Treat Cancer and Protect the Heart
NOVEL RNA-DIRECTED THERAPEUTICS TO TREAT CANCER AND PROTECT THE HEART AGM Presentation 23 November 2021 RACE ONCOLOGY LIMITED (ASX:RAC) 1 INVESTOR PRESENTATION
Slide 6: Disclaimer
DISCLAIMER Investment in Race Oncology (Race) is subject to investment risk, including possible loss of income and capital invested. Race does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation f
Slide 7: Why Invest Now?
WHY INVEST NOW? Clinical stage RNA focused company targeting multiple cancer indications with estimated annual oncology revenues of >US$2.6 billion Zantrene® first in class, best in class, most clinically advanced FTO inhibitor Expanding projects, pipeline and prospects New formulations to extend Za
Slide 8: Significant Commercial Opportunities
SIGNIFICANT COMMERCIAL OPPORTUNITIES NEW: CARDIO- NEW: OTHER RNA ONCOLOGY PROTECTION MOLECULES Annual revenue conservatively at Existing market with millions of Expanded opportunities in US$2.6 billion for AML, renal patients given anthracyclines each oncology, cardio-protection cancer and melanoma
Slide 9: Market Rationale
MARKET RATIONALE RACE ONCOLOGY LIMITED (ASX:RAC) 5 INVESTOR PRESENTATION
Slide 10: Precision Therapy: A Fundamental Change in the Treatment of Cancer and Other Diseases
PRECISION THERAPY: A FUNDAMENTAL CHANGE IN THE TREATMENT OF CANCER AND OTHER DISEASES STANDARDISED MEDICINE PERSONALISED MEDICINE Some benefit, some do not Each patient receives the right medicine for them Patients Patients Biomarker testing (eg FTO / m6A) Therapy Personalised Therapy Benefit No Ben
Slide 11: Problems with RNA Regulation Underlie Many Diseases
PROBLEMS WITH RNA REGULATION UNDERLIE MANY DISEASES Ribonucleic acid (RNA) is the key information messenger that translates genetic instructions from DNA (genes) to cell proteins CARDIAC CELL CANCER VIRAL Targeting RNA regulation pathways, like m6A methylation, RNA DYSREGULATION IS offers new treatm
Slide 12: FTO: m6A RNA Demethylase & Regulator
FTO: m6A RNA DEMETHYLASE & REGULATOR FTO is a key m6A RNA demethylase that is dysregulated in many cancers and other diseases1,2 WRITERS Zantrene® has been independently confirmed mRNA m6A as the first-in-class, best-in-class FTO inhibitor3 ERASERS TRANSLATION Race is advancing Zantrene® as the lead
Slide 13: FTO & Cancer: Broad Commercial Potential
FTO & CANCER BROAD COMMERCIAL POTENTIAL FTO TARGETABLE TUMOURS target markets INITIAL TARGET INDICATIONS AND ESTIMATED ANNUAL REVENUE RENAL MELANOMA AML Target Est. market ($USD) indication share Estimated FTO Addressable Melanoma 5% ~$1.3BN LUNG BREAST HEAD AND Oncology Market NECK >US$120 BILLION1
Slide 14: RNA Regulation Preclinical Pharma Deals, Significant Valuations
RNA REGULATION PRECLINICAL PHARMA DEALS SIGNIFICANT VALUATIONS SEP 21: OCT 21: Skyhawk raises OCT 21: Ipsen obtains an SEP 21: Exelixis deal of OCT 18: MAR 21: $600m in equity exclusive license to 858 Therapeutics US$17m upfront to Gotham Therapeutics Takeda pays $120m in funding and multiple commer
Slide 15: Corporate Strategy & Growth Plan
CORPORATE STRATEGY & GROWTH PLAN RACE ONCOLOGY LIMITED (ASX:RAC) 11 INVESTOR PRESENTATION
Slide 16: Three Pillar Strategy Optimised, Building Shareholder Value
THREE PILLAR STRATEGY OPTIMISED BUILDING SHAREHOLDER VALUE Capitalising on RNA regulation leadership credentials across all 3 Pillars ZANTRENE® ZANTRENE® BEYOND 1 2 OPTIMISED 3 ZANTRENE® Maximising Current Enhancing Zantrene® Utility Pursuing New Zantrene® Formulation With New Formulations RNA-Targe
Slide 17: Expanded Pipeline Targeting FTO & m6A RNA Methylation
EXPANDED PIPELINE TARGETING FTO & m6A RNA METHYLATION PRECLINICAL CLINICAL DISCOVERY IN VITRO IN VIVO PHASE I PHASE II REGISTRATION r/r AML (combination) Zantrene + fludarabine + clofarabine, Chaim Sheba Israel ZANTRENE® EMD AML (stratum 1) High Dose Zantrene + cytarabine *US IND 2022 1 EMD AML/MDS
Slide 18: New Programs
NEW PROGRAMS RACE ONCOLOGY LIMITED (ASX:RAC) 14 INVESTOR PRESENTATION
Slide 19: Zantrene Anthracycline Cardio-Protection
1 ZANTRENE® ANTHRACYCLINE CARDIO-PROTECTION • Heart damage from cancer therapies is a major and increasing issue as cancer patients live longer • Anthracyclines, anti-HER2, targeted agents and immuno- McGowan J et al Anthracycline Chemotherapy and Cardiotoxicity Cardiovasc Drugs therapies can all ca
Slide 20: Anthracycline Cardio-Protection Phase 2b Breast Cancer
1 ZANTRENE® ANTHRACYCLINE CARDIO-PROTECTION PHASE 2B BREAST CANCER • Commonly used anthracyclines like doxorubicin cause significant cardiac damage during cancer treatment Zantrene® & doxorubicin 100 • Prof Aaron Sverdlov & Dr Doan Ngo, University of 90 80 Newcastle 70 Cell viability (%) • Zantrene®
Slide 21: Optimised Companion Diagnostics
2 ZANTRENE® OPTIMISED COMPANION DIAGNOSTICS Companion diagnostic needed for precision medicine for both diagnosis and treatment monitoring TWO PROGRAMS UNDERWAY • FTO and global m6A RNA. Chaim Sheba, Prof Domanissi • m6A RNA genomics. University of Newcastle, Prof Murray COMPANION DIAGNOSTIC TO IDEN
Slide 22: Optimised Formulation Program: Extend and Enhance Zantrene
2 ZANTRENE® OPTIMISED FORMULATION PROGRAM. EXTEND AND ENHANCE ZANTRENE® Current Zantrene® formulation requires a two hour central line infusion Developing new Zantrene® formulations to allow peripheral infusion, shorter infusion times and less frequent administration IMPROVES ZANTRENE® UTILITY, IP P
Slide 23: New m6A RNA Targeting Molecules
NEW m6A RNA TARGETING MOLECULES BEYOND 3 ZANTRENE® Recent scientific and clinical discoveries implicate m6A RNA methylation in many disease areas RACE IS DEVELOPING NEW MOLECULES TO • Allow oral administration of an FTO inhibitor • Target other m6A RNA regulator proteins • Address non-cancer indicat
Slide 24: Share Placement Plan
SHARE PLACEMENT PLAN RACE ONCOLOGY LIMITED (ASX:RAC) 20 INVESTOR PRESENTATION
Slide 25: Share Purchase Plan Overview
SHARE PURCHASE PLAN OVERVIEW Race is launching a Share Purchase Plan (SPP) to provide existing shareholders the opportunity to invest in driving next steps across our highly promising clinical program. • Under the SPP, all eligible shareholders can subscribe for up to $30,000 in new RAC shares • SPP
Slide 26: Use of Funds: Base Case
USE OF FUNDS BASE CASE Proposed Expenditure FTO Solid Tumour FTO Solid Tumour (Phase 1/2) $8 million (Phase 1/2) Improved Improved Formulations $2.2 million Formulations Cardio-protection Cardio-protection (Preclinical) $1 million (Preclinical) New Molecules New Molecules $0.8 million Total $12 mill
Slide 27: Use of Funds: Mid Case
USE OF FUNDS MID CASE Proposed Expenditure FTO Solid Tumour (Phase 1/2) FTO Solid Tumour (Phase 1/2) $8 million Cardio-protection (Phase 2b) Cardio-protection (Phase 2b) $7.5 million Improved Formulations Improved Formulations $2.6 million Cardio-protection (Preclinical) Cardio-protection (Preclinic
Slide 28: Use of Funds: Full Case
USE OF FUNDS FULL CASE Proposed Expenditure FTO Solid Tumour (Phase 1/2) EMD AML (Phase 2 Europe) $9.2 million Cardio-protection (Phase 2b) FTO Solid Tumour (Phase 1/2) $8.0 million Improved Formulations Cardio-protection (Phase 2b) $7.5 million Cardio-protection (Preclinical) Improved Formulations
Slide 29: Share Purchase Plan Timetable
SHARE PURCHASE PLAN TIMETABLE* Date Item Record Date for Share Purchase Plan 8:00pm (AEST) Monday, 22nd November 2021 Announce Share Purchase Plan, Lodge Appendix 3B and issue Tuesday, 23rd November 2021 Cleansing Notice Share Purchase Plan booklet released to ASX Tuesday, 23rd November 2021 Opening
Slide 30: Race Oncology Limited (ASX:RAC) Investor Presentation
RACE ONCOLOGY LIMITED (ASX:RAC) 26 INVESTOR PRESENTATION
Racura Oncology — Shareholder Meeting (November 2021) on 6ix